Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q2 2018 · 10-Q
Revenue—
Net Income-$881.92K-$881.92KN/M vs Q2 2017 EPS Diluted$0.00$0.00— vs Q2 2017 Operating Income-$884,406N/M Operating Cash Flowderived-$789,535N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Jun 30, 2018 · filed Jul 23, 2018 · 23 d after period end